Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.

Authors:
Barbara Costa
Barbara Costa
University of Milano-Bicocca
Italy
Sara Bendinelli
Sara Bendinelli
University of Pisa
Italy
Pamela Gabelloni
Pamela Gabelloni
University of Pisa
Italy
Simona Daniele
Simona Daniele
University of Pisa
Italy
Fabrizio Scatena
Fabrizio Scatena
Pisana University Hospital
Renato Vanacore
Renato Vanacore
University of Pisa
Italy
Pietro Campiglia
Pietro Campiglia
University of Salerno

PLoS One 2013 19;8(8):e72281. Epub 2013 Aug 19.

Department of Pharmacy, University of Pisa, Pisa, Italy.

Cancer development and chemo-resistance are often due to impaired functioning of the p53 tumor suppressor through genetic mutation or sequestration by other proteins. In glioblastoma multiforme (GBM), p53 availability is frequently reduced because it binds to the Murine Double Minute-2 (MDM2) oncoprotein, which accumulates at high concentrations in tumor cells. The use of MDM2 inhibitors that interfere with the binding of p53 and MDM2 has become a valid approach to inhibit cell growth in a number of cancers; however little is known about the efficacy of these inhibitors in GBM. We report that a new small-molecule inhibitor of MDM2 with a spirooxoindolepyrrolidine core structure, named ISA27, effectively reactivated p53 function and inhibited human GBM cell growth in vitro by inducing cell cycle arrest and apoptosis. In immunoincompetent BALB/c nude mice bearing a human GBM xenograft, the administration of ISA27 in vivo activated p53, inhibited cell proliferation and induced apoptosis in tumor tissue. Significantly, ISA27 was non-toxic in an in vitro normal human cell model and an in vivo mouse model. ISA27 administration in combination with temozolomide (TMZ) produced a synergistic inhibitory effect on GBM cell viability in vitro, suggesting the possibility of lowering the dose of TMZ used in the treatment of GBM. In conclusion, our data show that ISA27 releases the powerful antitumor capacities of p53 in GBM cells. The use of this MDM2 inhibitor could become a novel therapy for the treatment of GBM patients.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0072281PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747081PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
January 2015
27 Reads
21 Citations
3.234 Impact Factor

Publication Analysis

Top Keywords

treatment gbm
8
mdm2 inhibitor
8
gbm cell
8
cells mdm2
8
gbm
8
cell growth
8
human gbm
8
glioblastoma multiforme
8
p53
7
cell
6
mdm2
6
isa27
5
gbm report
4
mice bearing
4
bearing human
4
nude mice
4
arrest apoptosis
4
apoptosis immunoincompetent
4
immunoincompetent balb/c
4
balb/c nude
4

References

(Supplied by CrossRef)
Advances in chemotherapy for brain tumors
CA Conrad et al.
Neurol Clin 1995
Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am
DT Nagasawa et al.
2012
Functions of the MDM2 oncoprotein
DA Freedman et al.
Cell Mol Life Sci 1999

Similar Publications